BARDA Provides the S
BARDA Provides the Sabin Vaccine Institute with an Additional $20 Million for Further Development of Ebola Sudan and Marburg Vaccines
13 mai 2020 07h00 HE | The Sabin Vaccine Institute
WASHINGTON, D.C. and ROME, Italy, May 13, 2020 (GLOBE NEWSWIRE) -- The Sabin Vaccine Institute (Sabin) and its partner ReiThera Srl today announced that the Biomedical Advanced Research and...
GOVX new logo.png
GeoVax Publishes Ebola Vaccine Study Results in Nature’s Scientific Reports
16 janv. 2018 09h00 HE | GeoVax, Inc.
ATLANTA, GA, Jan. 16, 2018 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, today announced publication of its manuscript entitled “A...
AbCellera Announces
AbCellera Announces Successful Completion of Collaboration for the Discovery of Fully Human Antibodies Against Pathogenic E. Coli and Ebola Virus
20 janv. 2016 19h13 HE | AbCellera
VANCOUVER, British Columbia, Jan. 20, 2016 (GLOBE NEWSWIRE) -- AbCellera announced today successful completion of its first antibody discovery partnership with MassBiologics of the University...
MMRGlobal to Grant Royalty-Free Licenses to Universities to Research Ebola Therapies Using Company's Patented Monoclonal Antibody Technology
05 août 2014 08h35 HE | MMRGlobal, Inc.
LOS ANGELES, CA--(Marketwired - Aug 5, 2014) - MMRGlobal, Inc. (OTCQB: MMRF) ("MMR") today announced that the Company plans on granting royalty-free licenses to universities interested in using the...